UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Qiagen (NYSE:QGEN - Free Report) by 6.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 492,302 shares of the company's stock after purchasing an additional 30,989 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.22% of Qiagen worth $21,922,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in the business. Geneos Wealth Management Inc. grew its stake in shares of Qiagen by 41.5% in the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock worth $38,000 after purchasing an additional 251 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its stake in shares of Qiagen by 3.6% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 9,816 shares of the company's stock worth $438,000 after purchasing an additional 341 shares during the last quarter. Pitcairn Co. grew its stake in shares of Qiagen by 5.3% in the 4th quarter. Pitcairn Co. now owns 6,996 shares of the company's stock worth $312,000 after purchasing an additional 354 shares during the last quarter. Headlands Technologies LLC grew its stake in shares of Qiagen by 2.0% in the 4th quarter. Headlands Technologies LLC now owns 19,823 shares of the company's stock worth $883,000 after purchasing an additional 397 shares during the last quarter. Finally, Moors & Cabot Inc. grew its stake in shares of Qiagen by 0.5% in the 4th quarter. Moors & Cabot Inc. now owns 86,474 shares of the company's stock worth $3,851,000 after purchasing an additional 426 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company's stock.
Qiagen Stock Up 1.2%
Shares of QGEN stock traded up $0.53 during trading on Thursday, hitting $44.91. 1,554,902 shares of the company were exchanged, compared to its average volume of 1,159,697. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. The firm has a market capitalization of $9.98 billion, a price-to-earnings ratio of 125.04, a P/E/G ratio of 2.39 and a beta of 0.67. The business's 50-day simple moving average is $41.59 and its 200 day simple moving average is $41.85. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30.
Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.50 by $0.05. The business had revenue of $483.46 million during the quarter, compared to analysts' expectations of $465.66 million. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The firm's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company posted $0.44 earnings per share. As a group, analysts forecast that Qiagen will post 2.26 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on QGEN shares. Robert W. Baird lifted their target price on shares of Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Wall Street Zen raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 15th. Redburn Atlantic downgraded shares of Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. UBS Group dropped their target price on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research report on Friday, February 7th. Finally, Baird R W downgraded shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $48.42.
Read Our Latest Stock Report on QGEN
About Qiagen
(
Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
Further Reading
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
